<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306329</url>
  </required_header>
  <id_info>
    <org_study_id>DNS-7801-201</org_study_id>
    <nct_id>NCT03306329</nct_id>
  </id_info>
  <brief_title>DNS-7801 vs. Placebo in Parkinson's Disease</brief_title>
  <acronym>PRIORITY</acronym>
  <official_title>A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dart NeuroScience, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dart NeuroScience, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient
      treatment study that will utilize standard Parkinson's Disease measures to evaluate the
      effect of DNS-7801
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative
  </why_stopped>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Maximal change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III from predose</measure>
    <time_frame>2-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change in OFF time from Baseline to Day 28 on home PD diary</measure>
    <time_frame>28-days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety of DNS-7801 evaluating the number of Treatment Emergent Adverse Events (TEAEs) at each study visit</measure>
    <time_frame>17-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Score on the Columbia Suicide Severity Rating Scale (C-SSRS) as assessed at each study visit</measure>
    <time_frame>17-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Tolerability of DNS-7801 assessed by discontinuation due to TEAE(s) [percent completers] at Day 10</measure>
    <time_frame>10-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III from Baseline to Day 28</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in ON time without troublesome dyskinesia from Baseline to Day 28</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from Baseline in the Parkinson's Disease Quality of Life Questionnaire Summary Index</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with improvement in Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Safety of DNS-7801 evaluating the number of Treatment Emergent Adverse Events (TEAEs) at each study visit</measure>
    <time_frame>35-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Score on the Columbia Suicide Severity Rating Scale (C-SSRS) as assessed at each study visit</measure>
    <time_frame>35-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Tolerability of DNS-7801 assessed by discontinuation due to TEAE(s) [percent completers]</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>DNS-7801 (low-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DNS-7801 (high-dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNS-7801 (low-dose)</intervention_name>
    <description>DNS-7801 (low-dose) tablets administered once daily.</description>
    <arm_group_label>DNS-7801 (low-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNS-7801 (high dose)</intervention_name>
    <description>DNS-7801 (high dose) tablets administered once daily.</description>
    <arm_group_label>DNS-7801 (high-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets administered once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Subjects who are diagnosed with Parkinson's disease as defined by the United Kingdom
             PD Society Brain Bank Criteria for the Diagnosis of PD.

          -  Modified Hoehn and Yahr Staging ≤ 3 in ON state.

          -  Mini Mental State Examination Score ≥ 26.

          -  Subjects must currently have a good response to levodopa and be receiving a stable
             dose of levodopa ( at least 4 doses per day of standard levodopa or ≥ 3 doses per day
             of Rytary™ (Carbidopa and levodopa Extended-Release Capsules) for at least 4 weeks
             prior to screening).

          -  Subjects must experience motor fluctuations with at least 2 hours of OFF periods each
             day in the awake time.

          -  Subjects must experience predictable early morning OFF periods.

          -  Subjects must be able to come to the clinic in the practically defined OFF state.

          -  Subject must have achieved the following results for home PD diary training, practice
             diary collection, and Baseline diary recordings (PART B ONLY):

               -  During a diary concordance session with an approved PD diary trainer/rater
                  (minimum 4 hours), subject achieved at least 80% overall diary concordance,
                  including at least 1 OFF interval.

               -  Returned a valid 2-day (i.e., 2 consecutive 24-hour periods) practice home PD
                  diary (as defined below).

               -  Returned valid diary recordings preceding the Baseline Visit that indicated at
                  least 2 hours of OFF time on each of the 2 days.

          -  All anti-parkinsonian medications must be maintained at a stable dose for at least 4
             weeks prior to the initial Screening Visit with the exception of monoamine oxidase-B
             inhibitors, which must be maintained at a stable level for at least 8 weeks prior to
             the screening visit.

        Main Exclusion Criteria:

          -  Diagnosis of secondary or an atypical Parkinsonian syndrome.

          -  Subject has severe disabling dyskinesia.

          -  Subject has clinically significant psychosis or hallucinations or history of psychosis
             in past 6 months.

          -  History of previous neurosurgery for PD.

          -  Currently or previously on Duopa/Duodopa.

          -  Currently on apomorphine or have received apomorphine within 30 days prior to
             baseline.

          -  The subject has a diagnosis or history of a substance related disorder (excluding
             nicotine and caffeine), including alcohol related disorder (Diagnostic and Statistical
             Manual of Mental Disorders 5 criteria) during the 12 months prior to the Screening
             Visit.

          -  The subject has tested positive at the Screening Visit for drugs of abuse (e.g.,
             opiates, cannabinoids, methadone, cocaine, and amphetamines [including ecstasy]).

          -  Any medical (including acute or chronic pain), surgical, or psychiatric condition,
             laboratory value, or concomitant medication which, in the opinion of the Investigator
             or the eligibility reviewer, makes the subject unsuitable for study entry or
             potentially unable to complete all aspects of the study.

          -  Suicidal ideation within 1 year prior to the Screening Visit as evidenced by answering
             &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of the Columbia Suicide
             Severity Rating Scale (C-SSRS) or attempted suicide within the last 5 years.

          -  Subjects with a current major depressive episode or a Beck Depression Inventory-II
             score of &gt; 19. Subjects receiving treatment for depression with antidepressants may be
             enrolled if they have been on a stable daily dose of the antidepressant for at least 8
             weeks before the Baseline Visit.

          -  Exposure to neuroleptics (antipsychotic drugs) for more than 1 month within the past 2
             years, or any exposure within the past year.

          -  Any malignancy in the 5 years prior to randomization (excluding basal cell carcinoma
             of the skin or cervical carcinoma in situ that have been successfully treated).

          -  Current or previous diagnosis of malignant melanoma or the presence of any suspicious
             skin lesion based on physical exam findings.

          -  Subjects, who, for any reason, are judged by the Investigator to be inappropriate for
             this study, including subjects who are unable to communicate or cooperate with the
             Investigator or who have/had a clinically significant illness or abnormal physical
             examination that may compromise safety of the subject during the trial or affect
             ability of the subject to adhere to study procedures

          -  Serum creatinine &gt; 2 mg/dL.

          -  Total serum bilirubin &gt; 2 mg/dL.

          -  Coagulation parameters (prothrombin time, activated partial thromboplastin time and
             international normalized ratio) and other laboratory parameters that, in the opinion
             of the Investigator, are in a range that could be harmful to the subject.

          -  Subjects with alanine transaminase or aspartate transaminase ≥ 3x upper limit of
             normal at Screening.

          -  Uncontrolled hypertension (e.g., Stage 2 hypertension - systolic &gt; 160 mm Hg or
             diastolic &gt; 100 mm Hg).

          -  Orthostatic hypotension that is symptomatic or requires medication.

          -  Subjects with heart block that, in the opinion of the Investigator, could interfere
             with the subject's ability to participate in the study.

          -  Hospitalization for myocardial infarction, ischemic heart disease, or congestive heart
             failure within the 12 months prior to the Screening Visit.

          -  Evidence on clinical examination or ECG of a clinically significant arrhythmia, as
             assessed by the Investigator.

          -  Subject is currently lactating or pregnant or planning to become pregnant during the
             study.

          -  Use of any medications that are prohibited concomitant medications during the study,
             are known to be strong or moderate inducers or inhibitors of cytochrome P450 (CYP)
             3A4, or are contraindicated for treatment with study drug.

          -  Consumption of grapefruit containing foods or beverages within 14 days before Baseline
             and for 14 days after the last dose of study drug.

          -  Subject is currently participating in or has participated in another study of a study
             drug or medical device in the last 3 months or within 5 half-lives of the study drug
             (whichever is longer) prior to Baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Perera, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dart NeuroScience, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC3 Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinsons Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Parkinson's Disease and Movement Disorders Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Institute PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

